Pancreatic Cancer Research

ResearcherChampalimaud FoundationActive in the last 2 years

John P. Neoptolemos

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6201-7399; OpenAlex author ID A5052825850, A5135134798. Sources: ClinicalTrials.gov.

Their work

Papers
138 (first author 8, last author 30)
Trials
1
Grants
0
Labs led
3
Collaborators
458
Papers, trials and grants by year

2001: 1 trial · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 5 papers · 2012: 6 papers · 2013: 5 papers · 2014: 8 papers · 2015: 6 papers · 2016: 9 papers · 2017: 7 papers · 2018: 15 papers · 2019: 9 papers · 2020: 8 papers · 2021: 19 papers · 2022: 8 papers · 2023: 14 papers · 2024: 5 papers · 2025: 7 papers · 2026: 7 papers

Papers 50 of 138

  1. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00601-1↗
  2. New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer. Last author DOI 10.1038/s41416-025-03295-9↗
  3. Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service. Co-author DOI 10.1038/s41416-026-03341-0↗
  4. NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer. Co-author DOI 10.1093/jnci/djaf345↗
  5. Neoadjuvant therapy for left-sided resectable pancreatic ductal adenocarcinoma: evidence-based shift or premature extrapolation? Last author DOI 10.21037/hbsn-2025-587↗
  6. Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic res… Co-author DOI 10.3892/or.2025.9027↗
  7. Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer Co-author DOI 10.64898/2026.10.06.756936↗
  8. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  9. GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. Co-author DOI 10.1016/j.esmogo.2025.100138↗
  10. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  11. Characterization of single neurons reprogrammed by pancreatic cancer. Co-author DOI 10.1038/s41586-025-08735-3↗
  12. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  13. Reply to: Adjuvant Treatment Options and Modalities in Pancreatic Adenocarcinoma: Insights From ESPAC4. Last author DOI 10.1200/jco-25-00333↗
  14. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Last author DOI 10.1200/jco.24.01118↗
  15. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  16. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Last author DOI 10.1016/j.tranon.2024.102109↗
  17. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  18. Tumour plasticity and tumour microenvironment interactions as potential immunologic targets for pancreatic cancer treatment. Last author DOI 10.21037/cco-24-72↗
  19. ESMO 2023 pancreatic cancer guidelines signal stepwise progress. Last author DOI 10.21037/hbsn-24-37↗
  20. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  21. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  22. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  23. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  24. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Last author DOI 10.1016/s2468-1253(22)00348-x↗
  25. Neoadjuvant therapy for pancreatic cancer. Last author DOI 10.1038/s41571-023-00746-1↗
  26. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Co-author DOI 10.1038/s43018-023-00628-6↗
  27. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  28. Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival. Last author DOI 10.1093/function/zqad011↗
  29. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  30. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  31. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  32. Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer. Last author DOI 10.1200/jco.23.00779↗
  33. Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. Last author DOI 10.3389/fcell.2023.1179559↗
  34. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  35. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Co-author DOI 10.1002/cnr2.1507↗
  36. A histopathological study of artery wall involvement in pancreatic cancer surgery. Co-author DOI 10.1007/s00423-022-02689-0↗
  37. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  38. CEND-1: a game changer for pancreatic cancer chemotherapy? First author DOI 10.1016/s2468-1253(22)00197-2↗
  39. The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain. First author DOI 10.1038/s41571-022-00612-6↗
  40. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  41. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  42. A Review of Pancreatic Cancer. Co-author DOI 10.1001/jama.2021.20065↗
  43. Neoadjuvant Chemotherapy in Pancreatic Cancer. Last author DOI 10.1001/jamasurg.2020.6273↗
  44. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. Co-author DOI 10.1002/gcc.22932↗
  45. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  46. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. Co-author DOI 10.1002/ueg2.12123↗
  47. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02080-5↗
  48. Periarterial divestment in pancreatic cancer surgery. Co-author DOI 10.1016/j.surg.2020.08.030↗
  49. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  50. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗

Trials 1

  1. Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Study chair NCT00058201↗

Closest collaborators

The 25 strongest of 458 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christoph Springfeld · 23 shared papers, 2019–2026 · strength 5.06
  2. Thilo Hackert · 35 shared papers, 2016–2026 · strength 4.85
  3. Markus Wolfgang Büchler · 45 shared papers, 2011–2026 · strength 4.67
  4. Paula Ghaneh · 31 shared papers, 2011–2026 · strength 2.86
  5. William Greenhalf · 40 shared papers, 2011–2026 · strength 2.53
  6. Eithne Costello · 40 shared papers, 2011–2026 · strength 2.30
  7. Christopher Michael Halloran · 24 shared papers, 2012–2026 · strength 2.16
  8. Peter J. Bailey · 11 shared papers, 2021–2025 · strength 1.97
  9. Christoph W. Michalski · 8 shared papers, 2013–2026 · strength 1.87
  10. Daniel H. Palmer · 20 shared papers, 2014–2025 · strength 1.74
  11. Oliver Strobel · 17 shared papers, 2016–2023 · strength 1.38
  12. Thomas P. Hank · 4 shared papers, 2021–2026 · strength 0.96
  13. Julia V. Mayerle · 13 shared papers, 2014–2024 · strength 0.92
  14. Daniel H. Palmer · 3 shared papers, 2026 · strength 0.78
  15. Jorg H. Kleeff · 10 shared papers, 2015–2020 · strength 0.78
  16. Juan W. Valle · 11 shared papers, 2014–2025 · strength 0.75
  17. Xu Zhou · 5 shared papers, 2021–2024 · strength 0.73
  18. Markus M. Lerch · 10 shared papers, 2016–2022 · strength 0.70
  19. Daniel Öhlund · 2 shared papers, 2026 · strength 0.69
  20. Gabriele Capurso · 10 shared papers, 2013–2023 · strength 0.68
  21. Bengt L. G. Glimelius · 10 shared papers, 2014–2025 · strength 0.65
  22. Susanne Roth · 4 shared papers, 2021–2024 · strength 0.65
  23. David Cunningham · 9 shared papers, 2014–2025 · strength 0.64
  24. Martin Loos · 3 shared papers, 2021–2026 · strength 0.57
  25. Faiyaz Notta · 4 shared papers, 2017–2026 · strength 0.57

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.